Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial
Authors' conclusion
Empagliflozin improved insulin sensitivity indexes in patients with a recent coronary event and drug naïve dysglycaemia. These findings support the safe use of empagliflozin as first-line glucose-lowering treatment in patients at very high cardiovascular risk with newly diagnosed dysglycaemia.
Study context
- Population
- Patients with recent MI or unstable angina and newly detected dysglycaemia (impaired glucose tolerance (IGT) or T2D); mean age 67.5 years, 19% femalesPatients with recent MI 36 · or unstable angina 6
- Participants
- 42 patients
- Comparison
- Empagliflozin 25 mg daily vs placebo
- Empagliflozinn = 20
- Placebon = 22reference
- Primary endpoint
- Insulin resistance, insulin sensitivity and β-cell function indexes (from 2-hour OGTT glucose and insulin and fasting C-peptide)
- Follow-up
- 7 months
Methodological detailsplacebo-controlled, Stress-perfusion cardiac MRI before randomization, 7 months after start of study drug and 3 months after cessation, Repeated measures ANOVA with treatment × visit interaction term
- Placebo-controlled
- Stress-perfusion cardiac MRI before randomization, 7 months after start of study drug and 3 months after cessation
- Repeated measures ANOVA with treatment × visit interaction term
Primary result
As reported in the abstract
Insulin resistance, sensitivity and β-cell function indexes
- Empagliflozin significantly improved insulin sensitivity indexes
- No impact on insulin resistance and β-cell function
Further findings
Glucose, insulin, C-peptide, mannose and HbA1c · 7 months
- Empagliflozin significantly decreased glucose and insulin values during the oral glucose tolerance tests (OGTT)
- C-peptide, mannose and HbA1c did not differ
Indexes after drug cessation · 3 months after cessation
- All indexes returned to initial levels
Insulin sensitivity indexes vs left ventricular mass · baseline
- Insulin sensitivity indexes inversely correlated with left ventricular mass
Original publication
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial. Cardiovasc Diabetol. Published 11 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →